CDA | Evidence Driven
CDA | Evidence Driven

Whole Breast Radiotherapy as Part of Breast Conserving Therapy

Details

Question

  1. What is the clinical effectiveness of hypofractionated whole-breast radiotherapy as part of breast-conserving therapy in people with breast cancer?
  2. What are the evidence-based guidelines regarding whole-breast radiotherapy as part of breast-conserving therapy in people with breast cancer?

Key Message

No evidence was identified about the clinical effectiveness of hypofractionated whole-breast radiotherapy as part of breast-conserving therapy in people with breast cancer.

Four evidence-based guidelines regarding whole-breast radiotherapy as part of breast-conserving therapy in people with breast cancer was identified.

Last Updated : July 20, 2022

Vandetanib for Medullary Thyroid Cancer

Details

This Drug Shortage Implementation Advice synthesizes the evidence on the efficacy and safety of therapeutic alternatives for medullary thyroid cancer and suggests preferred treatment options for use in the event of a supply shortage of vandetanib 100 mg.

 

Last Updated : July 13, 2022

Surveillance Colonoscopy Following Surgery for Colon Cancer

Details

Question

  1. What are the evidence-based guidelines regarding colonoscopic surveillance following colon cancer surgery?

Key Message

Twenty evidence-based guidelines describing colonoscopic surveillance following colon cancer surgery were identified.

Last Updated : July 7, 2022

Infliximab for Graft versus Host Disease

Details

Question

  1. What are the benefits and harms of Infliximab for graft-versus-host disease?

Key Message

Three non-randomized studies were found about the benefits and harms of Infliximab for graft-versus-host disease.

Last Updated : July 6, 2022

Azacitidine for Acute myeloid leukemia

Details

This custom health technology review will summarize evidence on the efficacy and safety of Azacitidine (intravenous and subcutaneous) as maintenance therapy for patients with Acute Myeloid Leukemia.

 

Last Updated : October 24, 2022

Private IV Infusion Clinics in Canada

Details

With the number of IV infusion therapies approved in Canada on the rise, and several in the pipeline for potential future approval, CADTH is assessing the readiness of the Canadian health care system to effectively implement these drugs. As a first step, CADTH has conducted a web search to collect information on the locations of privately funded IV infusion clinics across the country. To our knowledge, this is the first inventory of private IV infusion clinic locations in Canada.

Last Updated : June 24, 2022

Whole Brain Radiation Therapy for Patients With Limited Brain Metastases

Details

Question

  1. What is the comparative clinical effectiveness of whole brain radiation therapy versus stereotactic radiosurgery in patients with limited brain metastases?
  2. What are the evidence-based guidelines regarding the treatment of patients with limited brain metastases?

Key Message

No evidence was found about the comparative clinical effectiveness of whole brain radiation therapy versus stereotactic radiosurgery in patients with limited brain metastases.Thirteen evidence-based guidelines were identified about the treatment of patients with limited brain metastases.

Last Updated : June 20, 2022

Emerging Multi-Cancer Early Detection Technologies

Details

This Horizon Scan summarizes the available information regarding the emerging technology of liquid biopsy–based multi-cancer early detection tests for cancer screening. This scan focuses specifically on the Galleri (GRAIL Inc.) and CancerSEEK (Exact Sciences) tests, which are further along in the development cycle and are being assessed in different international clinical studies.

Last Updated : April 22, 2022

Radioiodine Resensitization for Radioiodine Refractory Metastatic Differentiated Thyroid Cancer

Details

Question

  1. What is the clinical effectiveness of radioiodine resensitization followed by radioiodine in patients with radioiodine-refractory/resistant metastatic differentiated thyroid cancer?
  2. What is the cost-effectiveness of radioiodine resensitization followed by radioiodine in patients with radioiodine-refractory/resistant metastatic differentiated thyroid cancer?

Key Message

Evidence of radioiodine resensitization was reported in 4 single-arm clinical trials and 3 uncontrolled retrospective cohort studies, which included between 3 and 20 patients. Over half of patients in these 7 studies demonstrated increased radioiodine avidity after resensitization treatment.Where reported, at least half of radioiodine retreated patients remained progression free and/or had not initiated a new treatment by the end of study follow-up.Adverse events associated with radioiodine resensitization therapies were typically mild, with skin-related adverse events being most common.No studies comparing outcomes of radioiodine resensitization therapies against lenvatinib or to no treatment were identified.No evidence on the cost-effectiveness of radioiodine resensitization therapy was found.

Last Updated : April 15, 2022

Everolimus for Functional Neuroendocrine Tumours of Gastrointestinal or Lung Origin

Details

Question

  1. What is the clinical effectiveness of everolimus for functional neuroendocrine tumours of lung origin?
  2. What is the clinical effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin?
  3. What is the cost effectiveness of everolimus for functional neuroendocrine tumours of lung origin?
  4. What is the cost effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin?
  5. What are the evidence-based guidelines regarding the use of everolimus for functional neuroendocrine tumours of gastrointestinal or lung origin?

Key Message

No evidence was identified regarding the clinical effectiveness of everolimus for functional neuroendocrine tumours of lung origin.

No evidence was identified regarding the clinical effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin.

No evidence was identified regarding the cost effectiveness of everolimus for functional neuroendocrine tumours of lung origin.

No evidence was identified regarding the cost effectiveness of everolimus for functional neuroendocrine tumours of gastrointestinal origin.

One evidence-based guideline was found regarding the use of everolimus for functional neuroendocrine tumours of gastrointestinal or lung origin.

Last Updated : April 6, 2022